MTOR and renal fibrosis: In conclusion, our results demonstrate that MSC treatment improves injured kidney architecture and reduces renal fibrosis by autophagic inhibition and by interfering with the mTOR signaling pathway via excreted exosomes containing mainly miRNA-122a.